We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Common Anti-Inflammatory Drugs Associated With Decreased Risk of Skin Cancer

By LabMedica International staff writers
Posted on 12 Jun 2012
Print article
A new study has found an association linking the use of various nonsteroidal anti-inflammatory drugs (NSAIDs) with a decreased risk of two major types of skin cancer.

Researchers at Aarhus University Hospital (Aarhus, Denmark) undertook a retrospective, population-based case-control study of patients in Northern Denmark to examine the association between use of NSAIDs--including aspirin, ibuprofin, and naproxen--and the risk of squamous cell carcinoma (SCC), basal cell carcinoma (BCC), and malignant melanoma (MM). Analysis of medical records from northern Denmark from 1991 through 2009 identified 1,974 diagnoses of SSC, 13,316 diagnoses of BCC, and 3,242 diagnoses of MM. Drug use information (including prescription data) from these patients was compared with information from 178,655 individuals without skin cancer.

Statistical analyses indicated that individuals who filled more than two prescriptions for NSAIDs had a 15% decreased risk for developing SCC and a 13% decreased risk for developing MM than those who filled two or fewer prescriptions for the medications, especially when the drugs were taken for seven or more years or taken at high intensity. Taking NSAIDs did not seem to reduce the risk of developing BCC in general, although there was a 15% and 21% reduced risk of developing BCC on less-exposed sites (body areas other than the head and neck) when the drugs were taken long term or at high intensity, respectively.

The main SCC and MM risk-reducers in the study were nonselective NSAIDs and older COX-2 inhibitors (diclofenac, etodolac, and meloxicam). NSAIDs are thought to help prevent the development of cancer by inhibiting cyclooxygenase (COX) enzymes, which are known to be involved in carcinogenesis.

“We hope that the potential cancer-protective effect of NSAIDs will inspire more research on skin cancer prevention,” said first author Sigrún Alba Jóhannesdóttir, BSc, of the Department of Clinical Epidemiology at Aarhus University Hospital; “Also, [this] effect should be taken into account when discussing benefits and harms of NSAID use.”

Related Links:
Aarhus University Hospital


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A massive study has identified new biomarkers for renal cancer subtypes, improving diagnosis and treatment (Photo courtesy of Jessica Johnson)

Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes

Renal cell carcinomas (RCCs) are notably diverse, encompassing over 20 distinct subtypes and generally categorized into clear cell and non-clear cell types; around 20% of all RCCs fall into the non-clear... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.